367 related articles for article (PubMed ID: 27819528)
21. Correlation of procalcitonin and cytokine expression with dehiscence of wartime extremity wounds.
Forsberg JA; Elster EA; Andersen RC; Nylen E; Brown TS; Rose MW; Stojadinovic A; Becker KL; McGuigan FX
J Bone Joint Surg Am; 2008 Mar; 90(3):580-8. PubMed ID: 18310708
[TBL] [Abstract][Full Text] [Related]
22. Pathogenesis and pharmacotherapy of Hidradenitis suppurativa.
Nazary M; van der Zee HH; Prens EP; Folkerts G; Boer J
Eur J Pharmacol; 2011 Dec; 672(1-3):1-8. PubMed ID: 21930119
[TBL] [Abstract][Full Text] [Related]
23. Hidradenitis suppurativa.
Brown TJ; Rosen T; Orengo IF
South Med J; 1998 Dec; 91(12):1107-14. PubMed ID: 9853721
[TBL] [Abstract][Full Text] [Related]
24. Topical management and wound care approaches for hidradenitis suppurativa.
Antia C; Alavi A; Alikhan A
Semin Cutan Med Surg; 2017 Jun; 36(2):58-61. PubMed ID: 28538745
[TBL] [Abstract][Full Text] [Related]
25. Hidradenitis suppurativa: the role of immune dysregulation.
Kelly G; Sweeney CM; Tobin AM; Kirby B
Int J Dermatol; 2014 Oct; 53(10):1186-96. PubMed ID: 24961484
[TBL] [Abstract][Full Text] [Related]
26. Local wound care and topical management of hidradenitis suppurativa.
Alavi A; Kirsner RS
J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S55-61. PubMed ID: 26470618
[TBL] [Abstract][Full Text] [Related]
27. Inflammatory Mechanisms in Hidradenitis Suppurativa.
Kelly G; Prens EP
Dermatol Clin; 2016 Jan; 34(1):51-8. PubMed ID: 26617358
[TBL] [Abstract][Full Text] [Related]
28. Vulvar hidradenitis suppurativa. Immunohistochemical evaluation of apocrine and eccrine involvement.
Heller DS; Haefner HK; Hameed M; Lieberman RW
J Reprod Med; 2002 Sep; 47(9):695-700. PubMed ID: 12380447
[TBL] [Abstract][Full Text] [Related]
29. A new T helper 17 cytokine in hidradenitis suppurativa: antimicrobial and proinflammatory role of interleukin-26.
Scala E; Di Caprio R; Cacciapuoti S; Caiazzo G; Fusco A; Tortorella E; Fabbrocini G; Balato A
Br J Dermatol; 2019 Nov; 181(5):1038-1045. PubMed ID: 30829398
[TBL] [Abstract][Full Text] [Related]
30. Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS).
Hessam S; Sand M; Gambichler T; Bechara FG
J Am Acad Dermatol; 2015 Dec; 73(6):998-1005. PubMed ID: 26410359
[TBL] [Abstract][Full Text] [Related]
31. Patients with hidradenitis suppurativa carry a higher systemic inflammatory load than other dermatological patients.
Riis PT; Søeby K; Saunte DM; Jemec GB
Arch Dermatol Res; 2015 Dec; 307(10):885-9. PubMed ID: 26350517
[TBL] [Abstract][Full Text] [Related]
32. Health care utilization patterns and costs for patients with hidradenitis suppurativa.
Kirby JS; Miller JJ; Adams DR; Leslie D
JAMA Dermatol; 2014 Sep; 150(9):937-44. PubMed ID: 24908260
[TBL] [Abstract][Full Text] [Related]
33. Hidradenitis Suppurativa in Patients With Inflammatory Bowel Disease: A Population-Based Cohort Study in Olmsted County, Minnesota.
Yadav S; Singh S; Edakkanambeth Varayil J; Harmsen WS; Zinsmeister AR; Tremaine WJ; Davis MD; Wetter DA; Colombel JF; Loftus EV
Clin Gastroenterol Hepatol; 2016 Jan; 14(1):65-70. PubMed ID: 25952308
[TBL] [Abstract][Full Text] [Related]
34. Hidradenitis Suppurativa: A Frequently Missed Diagnosis, Part 1: A Review of Pathogenesis, Associations, and Clinical Features.
Wang SC; Wang SC; Sibbald RG; Alhusayen R; Bashash M; Alavi A
Adv Skin Wound Care; 2015 Jul; 28(7):325-32; quiz 333-4. PubMed ID: 26080019
[TBL] [Abstract][Full Text] [Related]
35. Mast cells in hidradenitis suppurativa: a clinicopathological study.
List EK; Pascual JC; Zarchi K; Nürnberg BM; Jemec GBE
Arch Dermatol Res; 2019 May; 311(4):331-335. PubMed ID: 30877368
[TBL] [Abstract][Full Text] [Related]
36. Serum IL-36α, IL-36β, and IL-36γ levels in patients with hidradenitis suppurativa: association with disease characteristics, smoking, obesity, and metabolic syndrome.
Hayran Y; Allı N; Yücel Ç; Akdoğan N; Turhan T
Arch Dermatol Res; 2020 Apr; 312(3):187-196. PubMed ID: 31722038
[TBL] [Abstract][Full Text] [Related]
37. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
[TBL] [Abstract][Full Text] [Related]
38. Apocrine Gland-Rich Skin Has a Non-Inflammatory IL-17-Related Immune Milieu, that Turns to Inflammatory IL-17-Mediated Disease in Hidradenitis Suppurativa.
Jenei A; Dajnoki Z; Medgyesi B; Gáspár K; Béke G; Kinyó Á; Méhes G; Hendrik Z; Dinya T; Törőcsik D; Zouboulis CC; Prens EP; Bíró T; Szegedi A; Kapitány A
J Invest Dermatol; 2019 Apr; 139(4):964-968. PubMed ID: 30391261
[No Abstract] [Full Text] [Related]
39. Hidradenitis Suppurativa and the Association With Hematological Malignancies.
Sotoodian B; Abbas M; Brassard A
J Cutan Med Surg; 2017; 21(2):158-161. PubMed ID: 27573126
[TBL] [Abstract][Full Text] [Related]
40. Color Doppler ultrasound assessment of morphology and types of fistulous tracts in hidradenitis suppurativa (HS).
Wortsman X; Castro A; Figueroa A
J Am Acad Dermatol; 2016 Oct; 75(4):760-767. PubMed ID: 27498279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
